AU2006236928B2 - Method of altering the binding specificity of proteins by oxidation-reduction reactions - Google Patents

Method of altering the binding specificity of proteins by oxidation-reduction reactions Download PDF

Info

Publication number
AU2006236928B2
AU2006236928B2 AU2006236928A AU2006236928A AU2006236928B2 AU 2006236928 B2 AU2006236928 B2 AU 2006236928B2 AU 2006236928 A AU2006236928 A AU 2006236928A AU 2006236928 A AU2006236928 A AU 2006236928A AU 2006236928 B2 AU2006236928 B2 AU 2006236928B2
Authority
AU
Australia
Prior art keywords
antibody
protein
oxidizing agent
autoantibody
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006236928A
Other languages
English (en)
Other versions
AU2006236928A1 (en
Inventor
John A. Mcintyre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redox Reactive Reagents LLC
Original Assignee
Redox Reactive Reagents LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redox Reactive Reagents LLC filed Critical Redox Reactive Reagents LLC
Publication of AU2006236928A1 publication Critical patent/AU2006236928A1/en
Application granted granted Critical
Publication of AU2006236928B2 publication Critical patent/AU2006236928B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2006236928A 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions Ceased AU2006236928B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/108,826 US9557325B2 (en) 2003-06-09 2005-04-19 Method of altering the binding specificity of proteins by oxidation-reduction reactions
US11/108,826 2005-04-19
PCT/US2006/012802 WO2006113139A2 (en) 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions

Publications (2)

Publication Number Publication Date
AU2006236928A1 AU2006236928A1 (en) 2006-10-26
AU2006236928B2 true AU2006236928B2 (en) 2011-06-23

Family

ID=37115646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006236928A Ceased AU2006236928B2 (en) 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions

Country Status (9)

Country Link
US (1) US9557325B2 (enExample)
EP (1) EP1871171A4 (enExample)
JP (1) JP2008536920A (enExample)
CN (1) CN101262774A (enExample)
AU (1) AU2006236928B2 (enExample)
BR (1) BRPI0608373A2 (enExample)
CA (1) CA2602635C (enExample)
MX (1) MX2007013171A (enExample)
WO (1) WO2006113139A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
ATE518886T1 (de) 2003-06-09 2011-08-15 Redox Reactive Reagents L L C Verfahren zur änderung der bindungsspezifität von plasmaproteinen durch oxidations- reduktionsreaktionen
EP1805320B1 (en) * 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
AU2008298904B2 (en) * 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
US7989596B2 (en) * 2007-09-19 2011-08-02 Redox-Reactive Reagents Llc Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
EP2326952B1 (en) * 2008-09-04 2015-07-29 Redox-Reactive Reagents, Llc Method for diagnosing, monitoring, and/or staging alzheimer's disease
US20120107841A1 (en) * 2010-07-19 2012-05-03 Mcintyre John A Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CN102818896B (zh) * 2011-06-09 2014-12-17 北京华大蛋白质研发中心有限公司 一种基于特异抗体的硝基化修饰位点的检测方法及特异识别scot硝基化位点的抗体
ES2684976T3 (es) 2012-04-13 2018-10-05 Diabetomics, Inc. Biomarcadores maternos para diabetes gestacional
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
ES2748117T3 (es) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnóstico de una nueva enfermedad autoinmune
CN113490539A (zh) * 2019-05-29 2021-10-08 松下知识产权经营株式会社 检测方法和检测装置
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
CN118526489B (zh) * 2024-05-24 2025-04-01 南通大学 一种脱镁叶绿酸乙酯的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
WO2004111608A2 (en) * 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703001A (en) * 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
US5061790A (en) * 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
AU703814B2 (en) 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) * 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) * 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) * 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
WO2004111608A2 (en) * 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UCSF Children's Hospital, Patient Education: Baby Bottle Weaning http://web.archive.org/web/20040223230645/http://www.ucsfhealth.org/childrens/edu/bottleWeaning.html (23 February 2004) *

Also Published As

Publication number Publication date
US20050260681A1 (en) 2005-11-24
WO2006113139A2 (en) 2006-10-26
CN101262774A (zh) 2008-09-10
US9557325B2 (en) 2017-01-31
BRPI0608373A2 (pt) 2010-11-16
CA2602635C (en) 2014-12-23
JP2008536920A (ja) 2008-09-11
MX2007013171A (es) 2008-01-18
EP1871171A4 (en) 2015-08-19
WO2006113139A3 (en) 2007-08-23
CA2602635A1 (en) 2006-10-26
AU2006236928A1 (en) 2006-10-26
EP1871171A2 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
US10072068B2 (en) Method for altering the binding specificity of plasma proteins by oxidation
AU2006236928B2 (en) Method of altering the binding specificity of proteins by oxidation-reduction reactions
Tait et al. Solid phase HLA antibody detection technology–challenges in interpretation
Goldberg et al. Selective absence of IgA: A family study
McIntyre et al. Autoantibodies unmasked by redox reactions
McIntyre The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions
EP3650547A1 (en) Anti-human igg4 monoclonal antibody and human igg4 assay reagent using said antibody
US20250130245A1 (en) Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease
US7989596B2 (en) Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
AU2013200440B2 (en) Immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies and of polyreactive IgGs
McIntyre et al. Autoantibody potential of cancer therapeutic monoclonal antibodies
Lee et al. Distribution of anti-ABO immunoglobulin G subclass and C1q antibody in ABO-incompatible kidney transplantation
JPH08503770A (ja) 抗ｈｐａ抗体の検出
MXPA05013402A (en) Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
Mellbye et al. Human antibodies with specificity for the pepsin site of IgE

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired